|
gptkbp:instanceOf
|
gptkb:drug
SGLT2 inhibitor
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2012
|
|
gptkbp:ATCCode
|
A10BK01
|
|
gptkbp:brand
|
gptkb:Forxiga
gptkb:Farxiga
|
|
gptkbp:CASNumber
|
461432-26-8
|
|
gptkbp:chemicalClass
|
C-glycoside
|
|
gptkbp:contraindication
|
gptkb:diabetic_ketoacidosis
type 1 diabetes
severe renal impairment
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:discoveredBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:eliminationHalfLife
|
12.9 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:hasMolecularFormula
|
C21H25ClO6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dapagliflozin
|
|
gptkbp:IUPACName
|
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
|
|
gptkbp:KEGGID
|
D08917
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:mechanismOfAction
|
inhibits sodium-glucose co-transporter 2
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notRecommendedFor
|
children under 18
|
|
gptkbp:pregnancyCategory
|
Not recommended
|
|
gptkbp:prescribedWith
|
gptkb:metformin
gptkb:insulin
sulfonylureas
|
|
gptkbp:proteinBinding
|
91%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL66934
gptkb:DB06292
9887712
|
|
gptkbp:riskFactor
|
hypotension
increased urination
euglycemic diabetic ketoacidosis
volume depletion
increased risk of amputation (controversial)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
urinary tract infection
genital infection
hypoglycemia (with insulin or sulfonylurea)
|
|
gptkbp:UNII
|
T3P456416X
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes_mellitus
heart failure
chronic kidney disease
|
|
gptkbp:bfsParent
|
gptkb:Farxiga
gptkb:SGLT2_inhibitors
|
|
gptkbp:bfsLayer
|
6
|